Ana-I Velasco-Fernández

Prof. Dr. Ana-I Velasco-Fernández

Escuela Politécnica Superior, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ITI. Tusquets
I. Tusquets
MRM. Ramos
M. Ramos
MGM. Gil
M. Gil
PSP. Sánchez-Rovira
P. Sánchez-Rovira
JMJ. R. Mel
J. R. Mel
Ana-I Velasco-FernándezAna-I Velasco-Fernández
Ana-I Velasco-Fernández
10670 Background: T combined with weekly H confers greater tumor response and survival compared to T monotherapy in P with Her-2 positive MBC. A recent report has demonstrated that H can be administered q3wks. The primary endpoint is to evaluate time to progression (TTP). Sencondary objectives are response rate, overall survival and safety profile. Methods: P cytologically or histologically confirmed of metastatic breast cancer, HER-2 positive (+++ by Herceptest, or FISH positive), age > 18, ECOG PS ≤ 2, and adequate organ function, were included. Prior chemotherapy for MBC or adjuvant anthracycline-based regimen in the previous 6 months was not allowed. Treatment: T 100 mg/m2 iv D1 q3wks for 6 cycles, H 8 mg/kg (cycle 1) and 6 mg/kg (consecutive cycles) iv D1, q3wks. P may receive H monotherapy until PD at the investigator criteria. Results: Over 41 analyzed P, median age was 57 years (29–75); ECOG PS 0–1 95% and ductal carcinoma 88%. Twenty five P received prior chemotherapy. Treatment: 217 cycles of TH (median 6) were administered. After that, 23 P received 189 cycles of H monotherapy (median 5, 1–32). During TH treatment median RDI was 97% for T and 96% for H, and it was 99% during H treatment. Over 33 P for efficacy analysis (2 consent withdrawal, 1 allergic reaction, 1 ongoing and 4 response not confirmed by RECIST criteria), 6 achieved CR and 12 PR, for an ORR of 54.6% (95% CI: 37.6–71.6). Median follow-up time was 11.8 m and median TTP was 8.8 m (95% CI, 1.9–15.6). All P were evaluable for safety. During TH treatment, grade III/IV neutropenia occurred in 16 cycles (7.4 %), 14 of them were febrile neutropenia episodes (6.5%). Other grade III/IV toxicities per cycle were: leucopenia (5.5%), hyperglycemia (2.3%), anorexia (2.3%) and skin (2.3%). During H monotherapy treatment, the only grade III-IV toxicities observed were, skin (1.6%), oedema (1.1%), nail disorders (0.5%) and malaise (4.3%). Six P (14.6%) dropped out due to cardiac toxicity: 5 had LVEF under 50% and one atrial fibrillation. Conclusions: Preliminary results suggest that TH q3wks followed by H as single agent, is an effective regimen for the treatment of P with Her2 positive MBC. No significant financial relationships to disclose.

1 June 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PSP. Sánchez-Rovira
P. Sánchez-Rovira
AAA. Antón
A. Antón
MMM. Margelí
M. Margelí
Ana-I Velasco-FernándezAna-I Velasco-Fernández
Ana-I Velasco-Fernández
MLM. Lomas
M. Lomas
ECE. Carrasco
E. Carrasco
842 Background: GAT regimen has being tested as NC in LABC patients (pts), based on its efficacy in metastatic disease (Sanchez-Rovira et al. Oncology 2001; 15(2): 44–47). Methods: Newly diagnosed stage IIB-III non-inflammatory BC pts were enrolled in this phase II trial. 2 pathological complete responses (pCR) were needed among the first 29 pts to continue accrual (Simon’s test, 95% probability of 10% pCR). Doxorubicin (A) 40 mg/m2 was given on day 1 as a 15 minutes IV infusion; gemcitabine (G) 2000 mg/m2 and paclitaxel (T) 150 mg/m2 were given as a 60 minutes and 3 hours IV infusion respectively on day 2. Cycles (Cy) were administered biweekly for a total of 6 courses. The study was approved by appropriate ethics committees; informed consent was obtained for all pts. Results: 46 pts have been enrolled, median age was 49.6 years (range 30.1–72.5) and median tumour size 6 cm (range 3.0–14.0). 4 (8.7%) and 42 (91.3%) pts presented with stage IIB and III disease, respectively. 56.5% of pts were premenopausa...

1 June 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HCH. Cortes-Funes
H. Cortes-Funes
CAC. Almanza
C. Almanza
PVP. Valero
P. Valero
CGC. Garcia Giron
C. Garcia Giron
Ana-I Velasco-FernándezAna-I Velasco-Fernández
Ana-I Velasco-Fernández
RRR. Rosell
R. Rosell
7076 Background: The potential relevance of EGFR mut to non-small-cell lung cancer (NSCLC) treatment has recently been identified. We have examined the presence of EGFR mut in Spanish chemoresistant gefitinib-treated NSCLC patients (p). Methods: A total of 83 p were selected on the basis of availability of tumor specimens. EGFR exons 19 and 21 were amplified from genomic DNA and automatic sequencing was performed. Results: EGFR somatic mut in the tyrosine kinase domain were found in 10 of 83 p (12%). 8 mut were deletions in or near E746-A750, 3 of which carried insertions. The 2 remaining mut were L858R. Mut were more frequently observed in women (70%), adenocarcinomas (90%) and non-smokers (60%). p had received a median of 2 prior chemotherapy regimens. Median follow-up was 5 months (m) (range, 4.7–28.2). Duration of gefitinib: p with mut, 8.5 m, p with wild-type (wt), 3.1 m (P<0.001). Response: p with mut, 80%; p with wt, 8.8% (P<0.001). Time to progression from the start of gefitinib: all p, 3.9 m; p with mut, 12.3 m (95%CI, 6.4–18.3); p with wt, 3.6 m (95%CI, 2.6–4.7) (P=0.002). Median survival: all p, 5.7 m; p with mut, 13 m (95%CI, 6.5–19.4); p with wt, 4.9 m (95%CI, 3.8–5.9) (P=0.02). The Cox model indicated a 3.7 times higher risk of progression for p with wt, even adjusted for covariates, including gender and number of prior chemotherapy lines (P=0.005). Relative risk of death was 3.1 times higher for p with wt (P=0.03). Conclusions: This first study of its kind in Spain confirms that the presence of EGFR mutations is a major determinant of gefitinib response. Based on these results, a clinical trial of first-line gefitinib in lung adenocarcinomas harboring EGFR mut will be performed. No significant financial relationships to disclose.

6 March 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
EFEduardo Pilo de la Fuente
Eduardo Pilo de la Fuente
JGJaime Gros
Jaime Gros
MRMaría Antonia Simón Rodríguez
María Antonia Simón Rodríguez
Ana-I Velasco-FernándezAna-I Velasco-Fernández
Ana-I Velasco-Fernández
Carmen IniestaCarmen Iniesta
Carmen Iniesta
This paper presents a new procedure for the real-time processing and analysis of data from thermoacoustic systems. The approach focuses on continuously acquiring and adjusting measurements of acoustic wave pressure, enabling the instantaneous estimation of acoustic power. This is crucial for real-time control and decision-making, especially in applications that require rapid power estimation, such as the control loop implementation in thermoacoustic engines, where conditions are constantly changing and dynamic adaptation is essential. Two methods for estimating the power delivered to the load are proposed: (method 1) instantaneous power evaluation, which calculates the power consumed by the resistance in the resistance–capacitance (RC) load, and (method 2) one-period average power calculation using the well-established two-microphones method. These methods are validated with both different synthetic signals and experimental measurements. The results reveal that the new method provides real-time accurate estimations of the power delivered to the acoustic load and, thus, has shown potential for control-based applications.

28 August 2023
Verified
Book Chapter
Open access
PDF file
PMPilar Isabel Maldonado Muñoz
Pilar Isabel Maldonado Muñoz
JHJuan Miguel Garcia Haro
Juan Miguel Garcia Haro
MSMaria Antonia Simón
Maria Antonia Simón
Ana-I Velasco-FernándezAna-I Velasco-Fernández
Ana-I Velasco-Fernández
EBEva Bernardos
Eva Bernardos
En el presente artículo se expone el diseño y prototipado de una plantilla sensorizada para la monitorización de la pisada, cuya información y tratamiento a posterior puede tener una relevancia para la detección de posibles patologías o seguimiento de regímenes o terapias. Todos los datos extraídos a través de esta plantilla del pie serán procesados en tiempo real, a través del uso de sensores piezoresistivos de fuerza y la integración de una unidad de medición inercial. Además, todos estos datos van a ser almacenados para su posterior análisis y estudio, del cual se podría explorar su potencial uso y contribución en otras tecnologías asistidas (AT), así como otros usos fuera de este ámbito.